ARROWHEAD PHARMACEUTICALS, INC. (ARWR) stock intrinsic value fair value estimate & owner earnings analysis

Arrowhead Pharmaceuticals develops drugs that silence disease-causing genes using RNA interference. It has one approved product, REDEMPLO (plozasiran), cleared in the United States in late 2025 for familial chylomicronemia syndrome, a rare inherited triglyceride disorder. It also has a large clinical pipeline, much of it licensed to partners: Sarepta (neuromuscular and neurological programs), Novartis (ARO-SNCA for Parkinson's), Amgen (olpasiran, with the royalties already sold to Royalty Pharma), Madrigal (ARO-PNPLA3), GSK, Takeda and Sanofi (REDEMPLO in Greater China). Its own pipeline includes obesity and liver-fat programs such as ARO-INHBE and ARO-ALK7, and zodasiran, whose YOSEMITE study runs to mid-2027. Earnings record. We measure what an owner actually receives: operating cash flow with working-capital timing stripped out, less stock compensation and the capital spending needed to stay in business. On that basis Arrowhead earned money in only two of the last ten fiscal years. In fiscal 2019 it made $0.75 a share and in fiscal 2025 $1.00, and both years came from a large partner upfront booked as revenue (Janssen and Amgen in 2019, Sarepta's $500 million in 2025), not from operations. The other eight years ranged from a loss of $0.41 a share to a loss of $5.87 (fiscal 2024), and the losses have grown as the company has moved into late-stage trials and its own commercial launch. The first nine months of fiscal 2026 used $80 million of operating cash even after collecting more than $120 million of partner deferred revenue, and research spending ran at about $200 million a quarter. These figures replace the ones shown in our previous analysis, which treated growing working-capital balances and plant construction differently. Because there is no repeatable earning level to build on, we value the company the only way the facts allow: its cash, less its debts, plus or minus the cash its own operations will produce or consume. What it holds and owes. At June 30, 2026 Arrowhead held about $1.57 billion in cash and securities, which we reduce by $100 million kept for operations. Against that it owes about $350 million to settle the Sixth Street senior secured loan. That loan carries 15% interest paid by adding to the balance, and early repayment triggers minimum-return payments to the lender, so we count it at roughly what clearing it would cost rather than its $181 million book value. It also owes $700 million of zero-coupon convertible notes due January 2032 with conversion near $87 a share. Since conversion is far from certain, we treat them as debt; at today's value they are worth about $516 million. We leave out the $393 million royalty-sale liability to Royalty Pharma, because it is repaid only from Amgen's olpasiran royalties and never from Arrowhead's own cash. After debt, roughly $600 million of net financial assets remains. In addition, Sarepta owes $50 million a year in contracted installments through early 2030, worth about $180 million today. Base case: worth about minus $9.37 a share. REDEMPLO stays a small-population product. Its revenue is currently in the low single-digit millions a quarter, so it does not change the picture. We give no value to the much larger severe hypertriglyceridemia indication, because the sNDA has not yet been filed or approved. Partner milestones and royalties beyond the contracted Sarepta installments are not credited, since none is secured and their past timing has been erratic. Research, commercial and overhead spending, net of these minor revenues, runs at about $380 million a year for two years and then settles near $250 million a year, still above the 2016-2022 average because the company now carries a factory, a sales force and Phase 3 trials. The business, including the Sarepta installments, then consumes about $1.96 billion in today's money, against about $600 million of net financial assets. The company appears to owe and spend about $1.36 billion more than it has. In practice this means equity raises at whatever price prevails, which is how Arrowhead has funded itself for a decade: the diluted share count rose from 61 million to over 143 million in ten years. Bear case: worth about minus $13.98 a share. Spending stays at about $450 million a year for four years, with no relief from the severe hypertriglyceridemia program and no new licensing income, before cuts to about $300 million. This is the 2022-2024 pattern of rising losses repeated, not an invented catastrophe. In this case the convertible notes and the secured loan, which is backed by substantially all assets including the patents, would leave existing shareholders heavily diluted or wiped out. Bull case: worth about $11.48 a share. Plozasiran wins approval in severe hypertriglyceridemia from a 2026 filing under priority review, after SHASTA-3 and SHASTA-4 showed roughly 80% triglyceride reductions. The launch then builds to about $400 million a year of product contribution by the fourth year, and that income lasts through the early 2040s as patents age. Spending falls toward $200 million a year as late-stage trials finish. This is the one lever with real evidence behind it: positive Phase 3 data and an approved product on the market. Even so, it is a future regulatory event plus a market not yet won, so it belongs only in the best case. Beyond the patent life we credit nothing further: the platform has produced many licensing deals but only one commercial product in twenty years. What we may be getting wrong. First, the severe hypertriglyceridemia approval and launch: if it is approved and sells well, the median outcome moves sharply upward, which is why the margin of safety price depends on it. Second, partner income: Arrowhead has repeatedly signed large deals (Janssen, Amgen, Takeda, Horizon, GSK, Sarepta, Novartis, Madrigal), and a new one could cover a year of spending. We credit none because none is contracted, but the record shows they recur irregularly. Third, the obesity programs could attract a partner at a large price, but that is a hope, not a fact. Against all three stand a decade of growing cash consumption and steady dilution. Margin of safety price. We are not confident of any earnings level, because none has existed. The worst plausible outcome is a severe hypertriglyceridemia rejection or a slow launch while $450 million a year leaves the company. That would force financing, with a lender holding a first claim on the intellectual property. At present the business could survive it only by issuing a great deal of stock. Without the larger approval, no price clears our 20% annual hurdle with confidence, because the business consumes more than its net cash. Once that approval is in hand and REDEMPLO is selling at more than $150 million a year for two straight quarters with no new raise, the business would plausibly cover most of its own spending within three to four years. A price of $5 a share is roughly the net financial assets plus the contracted Sarepta installments, about $5.40 a share, with nothing assigned to the approved launch or the partnered pipeline. The price assumes a holding period of up to four years; the company pays no dividend. Our margin of safety price is $5, effective only once that condition is met. No going-concern doubt is raised in the filings. The company says it has enough liquidity for at least the next twelve months, and its cash covers roughly three years at the current rate of spending.